{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:03:18Z","timestamp":1771639398453,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10787-025-02087-0","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:52:24Z","timestamp":1767592344000},"page":"1081-1091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tapinarof in atopic dermatitis: a frequentist and bayesian meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"34","author":[{"given":"Rachita","family":"Meher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rituparna","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasish","family":"Hota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2087_CR1","doi-asserted-by":"publisher","first-page":"1361005","DOI":"10.3389\/fimmu.2024.1361005","volume":"15","author":"M Afshari","year":"2024","unstructured":"Afshari M, Kolackova M, Rosecka M, Celakovska J, Krejsek J (2024) Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Front Immunol 15:1361005","journal-title":"Front Immunol"},{"issue":"12","key":"2087_CR2","doi-asserted-by":"publisher","first-page":"adv00161","DOI":"10.2340\/00015555-3511","volume":"100","author":"F Ali","year":"2020","unstructured":"Ali F, Vyas J, Finlay AY (2020) Counting the burden: atopic dermatitis and Health-related quality of life. Acta Derm Venereol 100(12):adv00161","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"2087_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, Rucker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153\u2013160","journal-title":"Evid Based Ment Health"},{"issue":"4","key":"2087_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","volume":"166","author":"R Bissonnette","year":"2012","unstructured":"Bissonnette R, Poulin Y, Zhou Y et al (2012) Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol 166(4):853\u2013860","journal-title":"Br J Dermatol"},{"key":"2087_CR5","doi-asserted-by":"crossref","unstructured":"Broeders JA, Ahmed Ali U, Fischer G (2016) Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. J Am Acad Dermatol ; 75(2): 410-9 e3","DOI":"10.1016\/j.jaad.2016.02.1228"},{"issue":"4","key":"2087_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.det.2024.05.001","volume":"42","author":"MG Buethe","year":"2024","unstructured":"Buethe MG, Kellogg C, Seo YJ, Vuong C, Eichenfield LF (2024) Topical therapy for atopic dermatitis: what is new and the new paradigm. Dermatol Clin 42(4):569\u2013575","journal-title":"Dermatol Clin"},{"issue":"7","key":"2087_CR7","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1007\/s00210-024-02971-6","volume":"397","author":"XC Cao","year":"2024","unstructured":"Cao XC, Lu JW, Feng YF, Song LB, Lu Y (2024) Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a bayesian network analysis of RCTs. Naunyn Schmiedebergs Arch Pharmacol 397(7):4657\u20134662","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"2087_CR8","first-page":"33","volume":"2","author":"R Ceilley","year":"2009","unstructured":"Ceilley R, Eisenthal A (2009) The unintended effects of a boxed warning. J Clin Aesthet Dermatol 2(9):33\u201339","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"2087_CR9","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A et al (2024) Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 90(2):e43\u2013e56","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2087_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","volume":"7","author":"N Devasenapathy","year":"2023","unstructured":"Devasenapathy N, Chu A, Wong M et al (2023) Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health 7(1):13\u201325","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"2087_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG et al (2014) Guidelines of care for the management of atopic dermatitis: sect.\u00a02. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 71(1):116\u2013132","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2087_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E (2023) The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol 20(5):448\u2013474","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2087_CR13","doi-asserted-by":"publisher","first-page":"2444489","DOI":"10.1080\/09546634.2024.2444489","volume":"36","author":"LS Gold","year":"2025","unstructured":"Gold LS, Del Rosso J, Ehst BD et al (2025) Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials. J Dermatolog Treat 36(1):2444489","journal-title":"J Dermatolog Treat"},{"key":"2087_CR14","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ (2024) Welch VA Cochrane Handbook for Systematic Reviews of Interventions version 6.5. cochrane Database"},{"issue":"4","key":"2087_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/exd.14541","volume":"31","author":"J Hwang","year":"2022","unstructured":"Hwang J, Newton EM, Hsiao J, Shi VY (2022) Aryl hydrocarbon receptor\/nuclear factor E2-related factor 2 (AHR\/NRF2) signalling: a novel therapeutic target for atopic dermatitis. Exp Dermatol 31(4):485\u2013497","journal-title":"Exp Dermatol"},{"issue":"11","key":"2087_CR16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/1346-8138.17451","volume":"51","author":"A Igarashi","year":"2024","unstructured":"Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S (2024) Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials. J Dermatol 51(11):1404\u20131413","journal-title":"J Dermatol"},{"issue":"2","key":"2087_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1346-8138.17587","volume":"52","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tsuji G, Murata R, Fukasawa S, Yamane S (2025) A phase 2, randomized, double-blind, vehicle-controlled trial of Tapinarof cream in Japanese pediatric patients with atopic dermatitis. J Dermatol 52(2):247\u2013255","journal-title":"J Dermatol"},{"issue":"1","key":"2087_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.yapd.2023.03.006","volume":"70","author":"C Kellogg","year":"2023","unstructured":"Kellogg C, Smogorzewski J (2023) Update on atopic dermatitis. Adv Pediatr 70(1):157\u2013170","journal-title":"Adv Pediatr"},{"issue":"5","key":"2087_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamadermatol.2021.0345","volume":"157","author":"M Lam","year":"2021","unstructured":"Lam M, Zhu JW, Tadrous M, Drucker AM (2021) Association between topical calcineurin inhibitor use and risk of Cancer, including Lymphoma, keratinocyte Carcinoma, and melanoma: A systematic review and Meta-analysis. JAMA Dermatol 157(5):549\u2013558","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2087_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","volume":"184","author":"MR Laughter","year":"2021","unstructured":"Laughter MR, Maymone MBC, Mashayekhi S et al (2021) The global burden of atopic dermatitis: lessons from the global burden of disease study 1990\u20132017. Br J Dermatol 184(2):304\u2013309","journal-title":"Br J Dermatol"},{"issue":"8","key":"2087_CR21","first-page":"CD015064","volume":"8","author":"SJ Lax","year":"2024","unstructured":"Lax SJ, Van Vogt E, Candy B et al (2024) Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database Syst Rev 8(8):CD015064","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2087_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/ijd.17723","volume":"64","author":"R Mahajan","year":"2025","unstructured":"Mahajan R, Sarkar R, Panda M et al (2025) Evidence-Based recommendations for managing atopic dermatitis in pediatric patients: a systematic review and meta-analysis from the pediatric dermatology special interest group of IADVL. Int J Dermatol 64(7):1255\u20131266","journal-title":"Int J Dermatol"},{"issue":"1","key":"2087_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1","journal-title":"Syst Rev"},{"issue":"4","key":"2087_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1365-2133.2005.06899.x","volume":"153","author":"AD Ormerod","year":"2005","unstructured":"Ormerod AD (2005) Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 153(4):701\u2013705","journal-title":"Br J Dermatol"},{"key":"2087_CR25","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160","journal-title":"BMJ"},{"issue":"3","key":"2087_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","volume":"84","author":"AS Paller","year":"2021","unstructured":"Paller AS, Stein Gold L, Soung J, Tallman AM, Rubenstein DS, Gooderham M (2021) Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of Tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol 84(3):632\u2013638","journal-title":"J Am Acad Dermatol"},{"key":"2087_CR27","unstructured":"Prime MUE (2025) GRADEpro GDT: GRADEpro Guideline Development Tool [Software]."},{"key":"2087_CR28","doi-asserted-by":"crossref","unstructured":"Revolutionizing Atopic Dermatitis, 13 (2021) British J Dermat 185(3): e109-e46","DOI":"10.1111\/bjd.20648"},{"issue":"9","key":"2087_CR29","first-page":"e91549","volume":"17","author":"BA Saifi","year":"2025","unstructured":"Saifi BA, Saifi ZA, Emmanuel N (2025) Efficacy and safety of Tapinarof for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. Cureus 17(9):e91549","journal-title":"Cureus"},{"issue":"3","key":"2087_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA et al (2024) Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol 91(3):457\u2013465","journal-title":"J Am Acad Dermatol"},{"key":"2087_CR31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"9","key":"2087_CR32","first-page":"1265","volume":"19","author":"PC Wu","year":"2021","unstructured":"Wu PC, Huang IH, Liu CW, Huang YC (2021) Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis. J Dtsch Dermatol Ges 19(9):1265\u20131269","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02087-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:12:19Z","timestamp":1771636339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02087-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2087"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02087-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}